[Clinical significance of calcium channel blocker in patients with metabolic syndrome].
Diabetes mellitus, hyperlipidemia and hypertension are often coexisting, especially in obese subjects. Based on the close relationship between these abnormalities, the new definition of "Metabolic Syndrome" was established this April, in which "Metabolic Syndrome" was defined to have 2 of 3 abnormalities such as hypertriglyceridemia (>150 mg/dL) and/or low HDL-cholesterolemia (<40 mg/dL), hypertension (>130/85 mmHg) and high fasting glucose levels (>110 mg/dL) in addition to abdominal obesity (waist circumference >85 cm in men and >90 cm in women). It seems to be very important to select hypotensive agents which improve insulin sensitivity in hypertensive patients with "Metabolic Syndrome".
Katayama
Shigehiro
S
Division of Endocrinology and Meatbolism, Department of Medicine, Saitama Medical School.
D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D008297:Male; D024821:Metabolic Syndrome
D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers